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Results. RTOG acute toxicity was GU: G0 9(13%), G1 44(63.7%), G2 14(20,3%), G3 2(3%); GI G0 31(45%), G1 31(45%), G2 7 (11%), G3 0.
RTOG late toxicity was GU G0 46(66.6%), G1 18(26%), G2 4(5.8%), G3 1(1.4%); GI G0 61(88,4%), G1 7(10.1%), G2 1(1.5%). IPSS score: 11
before RT, 16.5 after and 9 at 3 months. Quality of life due to urinary symptoms was better at 3 months. QLQ-C30 global health
status was similar. QLQ-C30 functional scales: slight drop in physical and role functioning. QLQ-C30 symptoms scales: fatigue
and insomnia were slightly higher at 3 months. QLQ-PR25 functional scales of sexual activity and functioning were low in this
population and remained lower at 3 months. QLQ-PR25 symptoms scales: worsening of urinary and bowel symptoms after RT
but with recovery at 3 months. With a medium follow-up of 12 months there is not any biochemical relapse.
Conclusions. Acute and late toxicity of Hypofractionated VMAT-IGRT were light and similar than other series. QLQ impairment
was mild and acceptable. Further following is required to assess long term toxicity and disease control.
http://dx.doi.org/10.1016/j.rpor.2013.03.490
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Introduction. The low value of alfa/beta supports hypofractionated treatment schedules as therapeutic choice for prostate adeno-
carcinoma.
Objective. To explore a hypofractionated scheme as alternative therapeutic choice and demonstrate its potential beneﬁts, dose
escalation to 82Gy, keeping acute toxicity at an acceptable level while shorten the overall treatment length
Methods. In October 2011 our Department implemented a moderate hypofractionation treatment scheme as a new path-
way for prostate adenocarcinoma radiation treatment. Our hypofractionation protocol is based on a fraction dose of 2.6Gy
up to 82Gy 2Gy eq total dose, administered in 27 fractions. To derive the 82Gy isoefect dose “Dhypo” the LQ model was
used. Therefore, Dhypo=D2Gyx(d2Gy+a/b)/(dhypo+a/b) where a/b represents the ratio alfa/beta for prostate adenocarci-
noma. A value a/b=1.5 was selected (Brenner and Hall, 1999) and a/b=6 for normal tissue late reactions for rectum. It
follows Dhypo=82× (2 + 1.5)/(2.6 + 1.5) = 82×0.85=70.0Gy. Rounding off fractions number, the PTV prescribed dose is 70.2Gy,
2.6Gy/fraction, 27 fractions. IMRT dosimetry calculation and treatment administration was performed. Treatment was daily
image guided by Cone Beam CT. Patients were assigned to two study arms, each leaded by a clinician. First group maintained a
standard fractionation while second group scaled to 2.6Gy.
Results. In the period ranging from October 2011 and February 2013, 38 patients underwent daily CBCT image guided IMRT
hypofractionated treatment, 12 low-risk, 10 intermediate-risk and 16 high-risk. Reported RTOG/EORTC toxicity at genitourinary
level was G2:3, G1:16, G0:19. Rectal and intestinal toxicity G1:8, G0:30. Indication of pelvic lymph nodes irradiation for 11 of the 16
high-risk patients with intestinal toxicity G1:6, G0:5. Only one patient required urinary catheterization the last day of treatment
Conclusions. The obtained results show that hypofractionation is a suitable scheme for prostate adenocarcinoma treatment.
Length of treatment is shortened while keeping acute toxicity at a standard fractionation level.
http://dx.doi.org/10.1016/j.rpor.2013.03.491
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Purpose. To assess the impact of magnetic resonance imaging (MRI) staging for patients undergoing High Dose Rate (HDR)
brachytherapy with external beam radiotherapy (EBRT).
Methods and materials. Seventy consecutive patientswith intermediate risk andhigh risk prostate cancer underwent stagingmulti-
parametric MRI (high resolution TSE T2 in axial, sagital and coronal planes including the whole prostate and the seminal vesicles.
TSE T1 axial from pubic symphysis to iliac bifurcation. DWI SS, Volumetric 3D VISTA TSE-T, 3D spectroscopy, MR Perfusion, 3D
FFE T1 Fat Sat after intravenous administration of Gadolinium agent) The MRI ﬁndings were used to guide stage-appropriate
treatment recommendations, and to assist in the preplanning and optimization of the brachytherapy isodose distributions
